Maxim Seeks Ceplene Development Partner After FDA Request For More Data
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA indicates that approval of Ceplene for the treatment of acute myeloid leukemia would require confirmatory Phase III trial, Maxim says. The company previously withdrew an NDA for use of the oncologic in advanced malignant melanoma.
You may also be interested in...
EpiCept AML Drug Gets “Exceptional Circumstances” Stamp From EU Regulators
Remission maintenance drug should receive formal EC approval within 67 days; new U.S. filing planned for 2009.
EpiCept AML Drug Gets “Exceptional Circumstances” Stamp From EU Regulators
Remission maintenance drug should receive formal EC approval within 67 days; new U.S. filing planned for 2009.
Maxim Withdraws Ceplene Advanced Malignant Melanoma NDA
The company is shifting its focus for Ceplene to acute myeloid leukemia. Melanoma patients enrolled in the confirmatory Phase III trial will be allowed to complete their treatment regimen under a compassionate use program.